| Title |
Publication Date |
Price |
Relevance |
Apoptosis in Oncology
Pipeline Update 2010
|
January 2010 |
£1345 |
100 % |
Analytical Tool - Apoptosis in Oncology
|
January 2009 |
£2780 |
97 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£3095 |
94 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4645 |
85 % |
Analytical Tool: Apoptosis
Promise or deception?
|
January 2010 |
£2780 |
44 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£2475 |
38.5 % |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1750 |
35 % |
Target Atlas in Oncology Drug Development: Targeted Therapies
|
March 2009 |
£3680 |
28.5 % |
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
|
March 2009 |
£2780 |
27 % |
Triple Target Atlas in Oncology Drug Development
|
March 2009 |
£2780 |
27 % |
EpiCept Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£82 |
22.5 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1760 |
21 % |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£1760 |
16.8 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4440 |
15.05 % |
Prostate and Breast Cancer
New Treatments & Developmental Progress
|
March 2007 |
£2120 |
14.35 % |
Molecular Imaging in Drug R&D and Medical Practice
Technologies, Applications, Markets
|
January 2008 |
£735 |
14 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£2475 |
13.3 % |
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments
World Market
|
May 2007 |
£1300 |
13.3 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
12.6 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
12.25 % |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£5225 |
11.55 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£2475 |
11.2 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£5225 |
9.8 % |
Advances in Molecular Imaging
Companies and Technologies that are driving change
|
February 2010 |
£695 |
9.5 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£3095 |
9.45 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£3915 |
8.4 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£3915 |
8.05 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2220 |
8.05 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£3915 |
7.7 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£3095 |
7.7 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£3095 |
7 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£3095 |
7 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2610 |
6.65 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
March 2010 |
£2285 |
6.3 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£4960 |
5.95 % |
Biomarkers
Technologies, Markets and Companies
|
March 2010 |
£2940 |
4.2 % |
Nanobiotechnology
Applications, Markets and Companies
|
March 2010 |
£2940 |
3.85 % |
Personalized Medicine
Scientific & Commercial Aspects
|
March 2010 |
£2610 |
3.5 % |
